kawasaki
diseas
kd
acut
febril
childhood
inflammatori
diseas
associ
coronari
arteri
abnorm
diseas
believ
result
aberr
inflammatori
respons
infecti
trigger
genet
predispos
individu
kd
associ
endotheli
cell
injuri
consequ
cell
activ
cytotox
effect
variou
proinflammatori
cytokin
intraven
immunoglobulin
ivig
infus
aspirin
standard
treatment
acut
kd
howev
patient
show
resist
ivig
therapi
present
higher
risk
coronari
vascul
rel
role
second
ivig
infus
corticosteroid
calcineurin
inhibitor
antagonist
antitumor
necrosi
factor
agent
remain
uncertain
review
highlight
predispos
factor
pathogenesi
therapeut
intervent
kd
particularli
new
therapeut
ivigresist
patient
review
post
screen
kawasaki
diseas
kd
acut
febril
childhood
vascul
associ
develop
coronari
arteri
abnorm
kd
predominantli
affect
young
children
age
month
year
lead
caus
acquir
heart
diseas
among
children
japan
european
countri
usa
howev
kd
also
report
adult
kd
involv
predominantli
small
mediums
arteri
patient
complet
kd
usual
fever
least
day
durat
presenc
four
princip
featur
chang
peripher
extrem
polymorph
exanthema
bilater
nonexud
conjunctiv
inject
chang
oral
caviti
cervic
lymphadenopathi
cm
diamet
kd
believ
secondari
aberr
inflammatori
respons
infecti
trigger
genet
predispos
individu
three
distinct
diagnost
vasculopath
process
observ
sever
affect
kd
patient
necrot
arter
subacutechron
vascul
lumin
myofibroblast
prolifer
potenti
caus
lifelong
cardiovascular
sequela
death
review
focu
predispos
factor
pathogenesi
therapeut
intervent
kd
etiolog
basi
diseas
unclear
gener
accept
kd
due
one
wide
distribut
infecti
agent
evok
abnorm
immunolog
respons
genet
suscept
individu
genet
polymorph
encod
cytokin
chemokin
enzym
involv
signal
transduct
might
explain
differ
suscept
kd
well
respons
intraven
immunoglobulin
ivig
treatment
candid
kd
suscept
gene
like
blymphoid
tyrosin
kinas
blk
cluster
differenti
fcgammareceptor
inositoltriphosph
c
itpkc
caspas
identifi
genomewid
associ
studi
gwa
linkag
analysi
tabl
recent
studi
also
point
key
role
calcium
mobil
immunopathogenesi
kd
number
epidemiolog
clinic
observ
suggest
kd
secondari
infecti
agent
first
clinic
pictur
kd
overlap
infecti
diseas
adenoviru
scarlet
fever
second
season
cluster
kd
winter
spring
similar
viral
diseas
like
influenza
virus
enterovirus
fact
tempor
cluster
epidem
report
japan
usa
canada
finland
presenc
iga
plasma
cell
trachea
patient
die
acut
kd
suggest
entri
kd
etiolog
agent
upper
respiratori
tract
result
iga
immun
respons
system
spread
vascular
tissu
light
electron
microscopi
studi
demonstr
presenc
cytoplasm
inclus
bodi
inflam
tissu
acut
kd
inclus
bodi
suggest
infecti
etiolog
kd
result
intracellular
pathogen
particularli
virus
base
clue
obtain
clinic
epidemiolog
studi
investig
infecti
caus
kd
focus
mainli
superantigen
bacteri
toxin
viral
etiolog
superantigen
staphylococc
enterotoxin
streptococc
pyrogen
exotoxin
need
classic
antigen
process
present
antigenpres
cell
apc
superantigen
caus
extens
cell
prolifer
cytokin
secret
follow
direct
bind
major
histocompat
complex
class
ii
protein
surfac
apc
howev
specif
bacteria
superantigen
identifi
kd
scenario
clinic
featur
kd
similar
seen
patient
staphylococc
streptococc
toxinmedi
diseas
releas
proinflammatori
cytokin
interleukin
il
tumor
necrosi
factor
tnf
directli
relat
clinic
pictur
fever
mucos
involv
desquam
toxic
shock
syndrom
kd
infrequ
occurr
kd
among
young
infant
might
caus
passiv
acquir
matern
antibodi
toxic
shock
syndrom
toxin
tsst
superantigen
compar
control
group
patient
kd
like
posit
rate
viral
pcr
differ
virus
includ
enteroviru
adenoviru
rhinoviru
coronaviru
vs
p
previous
propos
group
normal
microflora
oral
caviti
gut
skin
parent
guardian
infant
young
children
etiolog
agent
kd
environment
factor
improv
public
hygien
western
lifestyl
industri
asian
countri
might
substitut
normal
flora
variant
also
kd
patient
asian
countri
hawaii
may
probabl
exposur
colon
kd
agent
distribut
normal
flora
parent
guardian
young
children
region
differ
western
countri
includ
franc
develop
countri
might
explain
differ
racial
incid
kd
genet
basi
suscept
kd
indic
sever
observ
compar
ethnic
incid
rate
kd
much
higher
among
japanes
individu
somewhat
lesser
degre
among
korean
taiwanes
popul
sibl
parent
affect
patient
also
show
increas
incid
kd
incid
rate
asian
higher
caucasian
number
patient
incid
rate
kd
japan
continu
increas
genet
basi
suscept
kd
complex
singl
hla
class
ii
haplotyp
common
patient
also
genet
factor
might
associ
racial
differ
kd
incid
tabl
show
candid
kd
suscept
gene
recent
gain
interest
genet
studi
adapt
immun
cell
compart
could
help
detect
sever
affect
kd
patient
genet
studi
provid
new
insight
pathogenesi
pathophysiolog
kd
transmiss
disequilibrium
studi
transmiss
disequilibrium
studi
demonstr
associ
kd
sever
singl
nucleotid
polymorph
snp
affect
function
molecul
involv
calcineurinnuclear
factor
activ
cell
nfat
pathway
transform
growth
factor
tgf
b
signal
pathway
fcg
receptor
fcgr
pathway
itpkc
regul
nodlik
receptor
famili
pyrin
domain
contain
activ
henc
product
via
control
ca
mobil
therefor
ca
mobil
play
major
part
immunopathogenesi
kd
polymorph
itpkc
might
result
increas
via
activ
data
sever
studi
show
snp
within
itpkc
gene
confer
suscept
kd
well
increas
risk
coronari
arteri
aneurysm
japanes
taiwanes
american
popul
itpkc
also
act
neg
regul
cell
activ
ca
nfat
signal
pathway
itpkc
polymorph
might
result
increas
activ
cell
increas
express
snp
within
gene
also
associ
suscept
kd
cohort
studi
asian
american
patient
found
g
substitut
one
commonli
associ
snp
locat
untransl
region
abolish
bind
nfat
dna
sequenc
surround
snp
genomewid
associ
studi
gwa
kd
publish
number
biolog
plausibl
loci
involv
inflamm
immun
respons
cardiovascular
statu
identifi
candid
kd
suscept
gene
identifi
gwa
includ
blk
blk
encod
b
lymphoid
tyrosin
kinas
src
famili
tyrosin
kinas
downstream
b
cell
receptor
express
surfac
cell
platelet
engag
drug
discoveri
today
volum
number
novemb
review
suscept
gene
kd
transmiss
disequilibrium
studi
transmiss
disequilibrium
studi
blk
gwa
gwa
gwa
hla
gwa
abbrevi
gwa
genomewid
associ
studi
itpkc
inositoltriphosph
c
kd
kawasaki
diseas
wwwdrugdiscoverytodaycom
express
surfac
apc
endotheli
cell
fcgriia
low
affin
activ
receptor
igg
provid
activ
signal
innat
immun
cell
recent
gwa
identifi
nebl
tubulin
alpha
novel
suscept
gene
associ
format
coronari
arteri
aneurysm
kd
kd
character
mark
immun
activ
associ
endotheli
cell
injuri
could
due
abnorm
cytokin
product
particularli
tnfa
gener
cytotox
antibodi
endotheli
cell
experiment
studi
mice
indic
possibl
role
pathogenesi
kd
also
suggest
sever
affect
kd
patient
giant
aneurysm
improp
immun
repair
system
kd
agent
injur
coronari
arteri
cell
mention
earlier
oligoclon
iga
plasmacel
infiltr
demonstr
arteri
wall
upper
respiratori
tract
pancrea
patient
acut
kd
suggest
antigendriven
immun
respons
etiolog
agent
respiratori
portal
entri
influx
neutrophil
character
earli
stage
kd
result
reactiv
oxygen
speci
inflammatori
mediat
contribut
endotheli
inflamm
infiltr
macrophag
lymphocyt
cellular
compon
arteri
wall
myofibroblast
also
import
diseas
pathogenesi
secret
number
inflammatori
mediat
enzym
molecul
vascular
endotheli
growth
factor
vegf
contribut
vascular
leakag
edema
presenc
circul
cytotox
antiendotheli
cell
antibodi
reactiv
antigen
vascular
endothelium
report
furthermor
igg
igm
antibodi
deriv
acut
kd
sera
report
caus
lysi
endotheli
cell
stimul
tnfa
antibodi
could
also
activ
immun
cell
upon
bind
activ
fcgr
fcgriia
express
highli
variou
innat
immun
cell
includ
macrophag
dendrit
cell
dc
neutrophil
therefor
stimul
fcgriia
result
activ
immun
cell
lead
express
activationassoci
surfac
molecul
costimulatori
molecul
secret
variou
inflammatori
cytokin
chemokin
note
function
polymorph
encod
substitut
identifi
suscept
locu
kd
addit
associ
genom
hypomethyl
suscept
kd
report
recent
studi
thu
provid
pointer
either
function
polymorph
epigenet
chang
lead
enhanc
fcgriia
signal
contribut
pathogenesi
kd
level
varieti
inflammatori
cytokin
tnfa
increas
serum
acut
kd
sever
studi
report
direct
correl
elev
level
acut
patient
vascular
endotheli
cell
damag
crucial
involv
lactobacillu
casei
cell
wall
extract
mediat
coronari
arter
myocard
seen
mous
model
kd
lesion
could
effici
prevent
receptor
antagonist
treatment
latest
result
group
indic
dc
macrophag
absolut
requir
l
casei
cell
wall
extract
induc
kd
vascul
model
macrophag
seem
cellular
sourc
lesion
analysi
serum
cytokin
level
kd
patient
reveal
tnfa
interferon
ifn
g
level
increas
significantli
ivig
treatment
addit
cell
proport
express
level
cytokin
associ
respons
also
significantli
upregul
kd
contrast
proport
regulatori
cell
treg
immunosuppressor
cell
crucial
maintain
immun
toler
prevent
inflammatori
respons
significantli
downregul
acut
kd
patient
proport
treg
also
express
level
treg
transcript
factor
significantli
downregul
patient
thu
current
hypothesi
infecti
agent
activ
innat
immun
cell
lead
ca
mobil
activ
lead
secret
enhanc
naiv
cell
surviv
prolifer
stimul
cell
fig
ivig
ivig
consist
pool
prepar
normal
human
igg
purifi
plasma
sever
thousand
healthi
donor
initi
use
replac
therapi
primari
secondari
immunodefici
patient
highdos
ivig
subsequ
use
treat
larg
number
autoimmun
inflammatori
disord
american
heart
associ
recommend
singl
administr
gkg
ivig
kd
patient
within
day
onset
fever
ivig
treatment
reduc
inflamm
fever
clinic
sign
acut
phase
reactant
level
also
importantli
prevent
develop
coronari
arteri
abnorm
reduc
risk
coronari
arteri
lesion
coronari
arteri
lesion
begin
occur
peak
inflamm
import
initi
ivig
therapi
within
week
fever
onset
ivig
exert
benefici
effect
via
sever
mutual
nonexclus
mechan
mechan
includ
inhibit
activ
innat
cell
dc
macrophag
monocyt
neutrophil
inflammatori
mediat
secret
modul
b
cell
respons
inhibit
autoantibodi
product
suppress
pathogen
cell
reciproc
enhanc
treg
inhibit
endotheli
cell
complement
activ
although
mechan
might
applic
kd
sever
demonstr
kd
patient
follow
ivig
therapi
tabl
sever
studi
shown
ivig
suppress
innat
inflammatori
cytokin
ivig
also
reduc
nitric
oxid
product
neutrophil
kd
patient
analysi
serum
cytokin
level
reveal
infg
decreas
rapidli
follow
ivig
treatment
contrast
ivig
reciproc
enhanc
express
treg
transcript
factor
genom
studi
report
express
activ
fcgr
fcgri
fcgriii
reduc
monocyt
ivig
therapi
ivig
inhibit
tnfainduc
nfkb
activ
monocyt
macrophag
block
fcgriii
surfac
howev
ivig
therapi
acut
stage
kd
increas
express
fcgriib
peripher
blood
monocyt
macrophag
unfortun
patient
display
ivig
resist
higher
risk
coronari
vascul
serum
level
remain
elev
refractori
patient
level
tnfa
decreas
significantli
ivig
treatment
kd
patient
without
coronari
arteri
lesion
increas
ivigtr
patient
coronari
lesion
ivigresist
kd
patient
even
treat
highdos
ivig
within
first
day
ill
children
kd
develop
least
transient
coronari
arteri
dilat
develop
giant
aneurysm
predict
resist
initi
ivig
treatment
kd
patient
riskscor
system
develop
take
account
age
durat
ill
initi
treatment
sever
blood
biochem
paramet
includ
platelet
neutrophil
count
alanin
aminotransferas
sodium
creactiv
protein
crp
although
score
demonstr
good
specif
low
pathogenesi
kawasaki
diseas
propos
infecti
trigger
activ
tlr
induc
accumul
itpkc
control
ca
homeostasi
phosphoryl
genomewid
associ
studi
report
polymorph
within
itpkc
gene
associ
suscept
sever
kawasaki
diseas
bind
receptor
express
endoplasm
reticulum
membran
caus
releas
ca
cytoplasm
ca
mobil
mediat
activ
certain
pamp
also
capabl
directli
activ
inflammasom
activ
inflammasom
result
cleavag
biolog
activ
form
shape
adapt
immun
respons
enhanc
naiv
cell
surviv
prolifer
via
upregul
receptor
addit
role
signal
cell
differenti
homeostasi
report
abbrevi
er
endoplasm
reticulum
il
interleukin
inositol
inositol
tetrakisphosph
itpkc
inositoltriphosph
c
nodlik
receptor
famili
pyrin
domain
contain
pamp
pathogenassoci
molecular
pattern
phosphatidylinositol
plc
phospholipas
c
ro
reactiv
oxygen
speci
tlr
tolllik
receptor
mechan
action
intraven
immunoglobulin
report
kawasaki
diseas
mechan
ivig
product
inflammatori
cytokin
tnfa
reduct
inflammatori
cytokin
product
neutrophil
activ
migrat
product
ro
nitric
oxid
reduct
nitric
oxid
product
neutrophil
monocyt
macrophag
activ
reduct
express
fcgri
fcgriii
monocyt
decreas
regulatori
express
increas
regulatori
cell
abbrevi
il
interleukin
ivig
intraven
immunoglobulin
ro
reactiv
oxygen
speci
tnf
tumor
necrosi
factor
wwwdrugdiscoverytodaycom
sensit
predict
resist
ivig
therapi
cohort
particularli
us
cohort
shed
uncertainti
univers
util
score
system
dysregul
immun
system
inflammatori
respons
hallmark
kd
number
inflammatorymediatorbas
biomark
damageassoci
molecular
pattern
molecul
granulocytecolonystimul
factor
tnfa
polycythemia
rubra
matrix
shown
potenti
predict
respons
ivig
therapi
resourcelimit
countri
ivig
therapi
gener
unavail
highdos
methylprednisolon
could
use
instead
ivig
aspirin
despit
lack
evid
support
therapeut
util
use
aspirin
kd
continu
wide
accept
practic
even
safeti
treatment
use
antiinflammatori
dose
debat
cochran
review
conclud
insuffici
evid
support
aspirin
use
kd
metaanalysi
compar
moderatedos
aspirin
mg
kg
per
day
highdos
aspirin
mgkg
per
day
combin
ivig
found
signific
differ
incid
coronari
abnorm
group
moder
dose
aspirin
use
acut
phase
low
antiplatelet
dose
mgkgday
use
follow
defervesc
lowdos
aspirin
continu
least
first
week
ill
time
risk
coronari
arteri
damag
greatest
control
clinic
data
lack
rel
role
repeat
dose
ivig
corticosteroid
tnfa
antagonist
cytotox
agent
methotrex
cyclophosphamid
cyclosporin
plasma
exchang
patient
refractori
kd
remain
uncertain
data
random
control
trial
exist
guid
treatment
patient
tabl
medic
center
howev
patient
remain
febril
persist
elev
serum
crp
level
treat
second
dose
ivig
gkg
new
guidelin
propos
recent
manag
kd
uk
take
consider
sever
diseas
prior
histori
ivig
resist
evolv
coronari
andor
peripher
aneurysm
ongo
inflamm
time
present
case
recommend
treat
patient
corticosteroid
ivig
respons
treatment
antitnfa
agent
consid
prednisolon
prospect
studi
one
retrospect
studi
use
intraven
prednisolon
refractori
kd
ogata
et
al
demonstr
steroid
puls
therapi
use
reduc
fever
durat
medic
cost
patient
kd
steroid
puls
therapi
addit
ivig
treatment
significantli
differ
term
prevent
develop
coronari
arteri
aneurysm
miura
et
al
report
kd
patient
unrespons
initi
ivig
treatment
intraven
methylprednisolon
therapi
suppress
cytokin
level
faster
subsequ
similar
addit
ivig
shown
addit
prednisolon
standard
regimen
ivig
improv
coronari
arteri
outcom
patient
sever
kd
japan
howev
anoth
trial
north
american
patient
mix
ethnic
unabl
demonstr
benefit
primari
steroid
treatment
prospect
classif
patient
high
versu
low
risk
ivig
resist
antitnf
therapi
infliximab
monoclon
antibodi
tnfa
suppress
cytokinemedi
inflamm
phase
iii
random
doubleblind
placebocontrol
trial
explor
use
infliximab
primari
treatment
kd
along
ivig
howev
addit
infliximab
primari
treatment
acut
kd
reduc
treatment
resist
studi
explor
util
infliximab
refractori
kd
prospect
trial
burn
et
al
shown
infliximab
second
ivig
infus
safe
welltoler
subject
kd
resist
standard
ivig
treatment
anoth
retrospect
studi
demonstr
patient
ivigresist
kd
whose
first
retreat
infliximab
faster
resolut
fever
fewer
day
hospit
compar
treat
ivig
coronari
arteri
outcom
advers
event
similar
group
prospect
studi
demonstr
treatment
prospect
studi
prospect
studi
retrospect
studi
prospect
studi
infliximab
prospect
studi
retrospect
studi
case
seri
prospect
studi
cyclosporin
retrospect
studi
retrospect
studi
case
seri
oral
methotrex
retrospect
studi
case
seri
cyclophosphamid
retrospect
studi
anakinra
case
report
case
report
case
report
ivigresist
patient
infliximab
lead
shorter
durat
fever
fewer
day
hospit
patient
retreat
ivig
howev
differ
observ
coronari
outcom
advers
event
phase
iii
trial
assess
safeti
efficaci
infliximab
ivigresist
kd
complet
clinicaltrialsgov
current
placebocontrol
doubleblind
random
studi
ongo
determin
etanercept
mgkg
subcutan
given
three
time
weekli
interv
start
initi
diagnosi
safe
success
adjunct
therapi
ivig
reduc
incid
persist
recurr
fever
kd
clinicaltrialsgov
cyclosporin
potenti
role
calcineurin
inhibitor
manag
kd
two
retrospect
studi
one
case
seri
explor
potenti
use
cyclosporin
refractori
kd
tremoulet
et
al
demonstr
cyclosporin
safe
effect
approach
achiev
rapid
control
inflamm
clinic
improv
flowcytometrybas
analysi
cell
phenotyp
two
subject
display
reduct
circul
activ
effector
memori
cell
follow
cyclosporin
treatment
howev
suppress
treg
observ
oral
methotrex
one
retrospect
studi
one
case
seri
examin
use
oral
methotrex
refractori
kd
lee
et
al
treat
patient
resist
one
infus
ivig
lowdos
oral
methotrex
mgm
weekli
administr
methotrex
continu
crp
level
normal
patient
experienc
fast
resolut
fever
rapid
improv
inflamm
marker
without
advers
effect
howev
treatment
rare
use
atorvastatin
atorvastatin
select
competit
inhibitor
hmgcoa
reductas
addit
cholesterollow
effect
statin
exert
improv
endotheli
function
reduct
proinflammatori
cytokin
chemokin
openlabel
noncompar
phase
ii
trial
ongo
evalu
effect
atorvastatin
persist
coronari
arteri
aneurysm
children
kd
clinicaltrialsgov
cyclophosphamid
wallac
et
al
treat
success
two
kd
patient
refractori
two
cure
ivig
intraven
methylprednisolon
intraven
cyclophosphamid
mgkgday
progress
coronari
aneurysm
observ
patient
receptor
antagonist
three
case
report
explor
efficaci
drug
kd
two
patient
also
macrophag
activ
syndrom
along
kd
anakinra
recombin
receptor
antagonist
use
mg
kgday
success
kd
mice
atherosclerosi
lcaseiinduc
coronari
arter
treat
anakinra
found
daili
inject
anakinra
prevent
acceler
atherosclerosi
current
two
clinic
trial
ongo
explor
efficaci
anakinra
kd
phase
iia
multicent
trial
aim
assess
efficaci
safeti
anakinra
patient
kd
fail
respond
standard
treatment
ie
one
infus
gkg
ivig
clinicaltrialsgov
anoth
phase
ii
trial
intend
assess
safeti
activ
anakinra
infant
children
year
old
coronari
arteri
abnorm
clinicaltrialsgov
plasma
exchang
mori
et
al
report
effect
plasma
exchang
kd
patient
refractori
ivig
comparison
outcom
children
given
plasma
exchang
treatment
receiv
indic
plasma
exchang
significantli
reduc
frequenc
acutephas
coronari
lesion
versu
p
anoth
studi
patient
refractori
kd
treat
plasma
exchang
outcom
favor
effect
excel
particularli
initi
coronari
arteri
lesion
aris
patient
kd
refractori
ivig
therapi
biomark
predict
ivig
resist
respons
need
reduc
morbid
treatment
cost
initi
altern
therapi
resist
patient
promptli
howev
altern
therapi
explor
resist
patient
lack
data
random
control
studi
make
treatment
refractori
kd
difficult
therefor
result
random
clinic
trial
tnfa
inhibitor
much
await
expect
provid
option
manag
resist
patient
improv
option
treatment
kd
could
deriv
data
pathogenet
mechan
diseas
recent
evid
show
ca
mobil
play
major
part
pathogenesi
kd
mediat
inflammasom
activ
convert
activ
cleav
biolog
activ
form
potent
select
small
molecul
inhibitor
potent
select
small
molecul
inhibitor
shown
promis
variou
experiment
model
autoimmun
inflammatori
diseas
combin
ivig
inflammasom
inhibitor
might
examin
refractori
patient
author
conflict
interest
declar
